Immuneering Corporation Expands Alliance with Bristol-Myers Squibb CAMBRIDGE, Mass., Jan. 29, 2014 /PRNewswire/ — Immuneering Corporation announced today that it has entered into an agreement to expand its existing relationship…
Read More
Jan. 13, 2014– Teva Pharmaceuticals Industries Ltd. and Immuneering Corporation have co-authored a publication in PLOS ONE demonstrating that key genes respond differently to COPAXONE® (glatiramer acetate injection) versus a…
For decades, policies regarding generic medicines have sought to provide patients with economical access to safe and effective drugs, while encouraging the development of new therapies. This balance is becoming…
June 2, 2013 – Immuneering CEO Ben Zeskind was interviewed during the 2013 ASCO Annual Meeting as part of a series of videos produced by the Society for Immunotherapy of…
April 3, 2013. Cambridge, MA. Immuneering Corporation is pleased to announce the publication of “Defining the Transcriptional and Cellular Landscape of Type 1 Diabetes in the NOD Mouse” in PLoS…
Our ability to successfully intervene in disease processes is dependent on definitive diagnosis. In the case of autoimmune disease, this is particularly challenging because progression of disease is lengthy and…
Cambridge, MA. February 14, 2013. Today Immuneering celebrates 5 years in business. Since the company’s founding in early 2008, Immuneering has helped many of the world’s top pharmaceutical and biotechnology…
October 25, 2012 — Immuneering’s CEO (Ben Zeskind, PhD, MBA) will moderate a plenary session at the 4th Translational Medicine Conference, and give a talk entitled “Predicting Response and Understanding…
The article “Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study” by de Groot et al1 was published in Journal of Clinical Oncology….
Clinical Cancer Research recently published an important study by Coward and colleagues (1) examining interleukin-6 as a target in ovarian cancer and last year published an investigation of the same…
